- TRYNGOLZA ® (olezarsen) showed increasing demand in FCS driven by strong launch execution – - Olezarsen sNDA accepted by the FDA for Priority Review; sHTG launch preparations on track – – Increasing annual TRYNGOLZA peak net sales guidance to > $3B for sHTG – - Zilganersen NDA for Alexander
Ionis reports first quarter 2026 financial results and highlights progress on key programs
calendar_today
April 29, 2026
person
Ionis Pharmaceuticals, Inc. News Releases
domain
ionis-pharmaceuticals